Guiyang Xintian Pharmaceutical Co.,Ltd.

SZSE:002873 Stock Report

Market Cap: CN¥2.1b

Guiyang Xintian PharmaceuticalLtd Management

Management criteria checks 3/4

Guiyang Xintian PharmaceuticalLtd's CEO is Da Lun Dong, appointed in May 2005, has a tenure of 19.58 years. directly owns 36.58% of the company’s shares, worth CN¥761.31M. The average tenure of the management team and the board of directors is 12.3 years and 5.1 years respectively.

Key information

Da Lun Dong

Chief executive officer

CN¥1.3m

Total compensation

CEO salary percentagen/a
CEO tenure19.6yrs
CEO ownership36.6%
Management average tenure12.3yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Why Guiyang Xintian PharmaceuticalLtd's (SZSE:002873) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 04
Why Guiyang Xintian PharmaceuticalLtd's (SZSE:002873) Shaky Earnings Are Just The Beginning Of Its Problems

Earnings Tell The Story For Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) As Its Stock Soars 25%

Oct 01
Earnings Tell The Story For Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) As Its Stock Soars 25%

Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Jun 05
Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)

Apr 19
Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)

Investors Still Aren't Entirely Convinced By Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Earnings Despite 28% Price Jump

Mar 11
Investors Still Aren't Entirely Convinced By Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Earnings Despite 28% Price Jump

CEO

Da Lun Dong (60 yo)

19.6yrs

Tenure

CN¥1,320,000

Compensation

Mr. Da Lun Dong has been Chairman of the Board at Guiyang Xintian Pharmaceutical Co., Ltd. since December 2001 and has been its General Manager since May 01, 2005. Mr. Dong has been Executive director of G...

Leadership Team

NamePositionTenureCompensationOwnership
Da Lun Dong
GM & Chairman of the Board19.6yrsCN¥1.32m36.58%
CN¥ 761.3m
Jin Hua Wang
Vice Chairman & Deputy GM29.3yrsCN¥600.00k2.91%
CN¥ 60.7m
Zhihui Zeng
CFO & Accounting Supervisor5.1yrsCN¥600.00k0.036%
CN¥ 743.9k
Guangping Wang
Deputy GM4.3yrsCN¥720.00k0.025%
CN¥ 521.4k

12.3yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 002873's management team is seasoned and experienced (12.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Da Lun Dong
GM & Chairman of the Board23yrsCN¥1.32m36.58%
CN¥ 761.3m
Jin Hua Wang
Vice Chairman & Deputy GM29.3yrsCN¥600.00k2.91%
CN¥ 60.7m
Guangping Wang
Deputy GM2.6yrsCN¥720.00k0.025%
CN¥ 521.4k
Wen Yi Wang
Director11.8yrsCN¥744.00k0.15%
CN¥ 3.2m
Weijia Ji
Director5.7yrsCN¥461.50k0.045%
CN¥ 937.9k
Heyu You
Supervisor5.7yrsno data0.0084%
CN¥ 174.8k
Wanxue An
Supervisory Board Chairman5.1yrsno data0.039%
CN¥ 812.4k
Zhonglei He
Non-Independent Director2.6yrsCN¥364.70k0.018%
CN¥ 364.9k
Feng Guan
Independent Director3.3yrsCN¥110.00kno data
Jie Zhang
Independent Director3.3yrsCN¥110.00kno data
Ruzhen Jin
Non-Employee Supervisor5.1yrsno datano data

5.1yrs

Average Tenure

50yo

Average Age

Experienced Board: 002873's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:08
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guiyang Xintian Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mengmeng HanPing An Securities Co. Ltd.
Song YangTianfeng Securities Brokerage Co., Ltd